# Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

> **NCT02097459** · PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 600 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Tamoxifen
- **DRUG:** Toremifene

## Key facts

- **NCT ID:** NCT02097459
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2024-03
- **Final completion:** —
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2016-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097459, "Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02097459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*